Low Level DUX4 Expression Disrupts Myogenesis Through Deregulation of Myogenic Gene Expression

Overview

Journal Sci Rep

Specialty Science

Date 2018 Nov 18

PMID 30446688

Citations 32

Authors

Darko Bosnakovski

Micah D Gearhart

Erik A Toso

Elizabeth T Ener

Si Ho Choi

Michael Kyba

Affiliations

Soon will be listed here.

Abstract

Loss of silencing of the DUX4 gene on chromosome 4 causes facioscapulohumeral muscular dystrophy. While high level DUX4 expression induces apoptosis, the effects of low level DUX4 expression on human myogenic cells are not well understood. Low levels and sporadic expression of DUX4 have been reported in FSHD biopsy samples and myoblast cultures. Here, we show that a large set of human myogenic genes is rapidly deregulated by DUX4, including MYOD1 and MYF5, which are efficiently repressed even by low, non-toxic levels of DUX4. Human myoblasts modified to express low nontoxic levels of DUX4 were significantly impaired from differentiating into myotubes in vitro. Surprisingly, inhibition of differentiation does not require the transcriptional activation domain, thus is likely a feature of all mammalian DUX genes. DUX4 does not bind near the MYF5 gene, but has a prominent ChIP-seq peak within the MYF5 -118 kb enhancer. We find that when DUX4 binds at this site, it directs enhancer activity towards a nearby transcriptional start site for a noncoding nonfunctional RNA we name DIME (DUX4-induced MYF5 enhancer) transcript. These data highlight the anti-myogenic properties of DUX4 in human myogenic progenitor cells, and provide an example of enhancer disruption in the downregulation of MYF5.

Citing Articles

SIX transcription factors are necessary for the activation of DUX4 expression in facioscapulohumeral muscular dystrophy.

Fox A, Oliva J, Vangipurapu R, Sverdrup F Skelet Muscle. 2024; 14(1):30.

PMID: 39627769 PMC: 11613756. DOI: 10.1186/s13395-024-00361-3.

Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy.

Vangipurapu R, Oliva J, Fox A, Sverdrup F Sci Rep. 2024; 14(1):26437.

PMID: 39488616 PMC: 11531483. DOI: 10.1038/s41598-024-77911-8.

Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.

Arends T, Hamm D, van der Maarel S, Tapscott S Cold Spring Harb Perspect Biol. 2024; .

PMID: 39009417 PMC: 11733064. DOI: 10.1101/cshperspect.a041492.

French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD).

Attarian S, Beloribi-Djefaflia S, Bernard R, Nguyen K, Cances C, Gavazza C J Neurol. 2024; 271(9):5778-5803.

PMID: 38955828 DOI: 10.1007/s00415-024-12538-3.

Meta-analysis towards FSHD reveals misregulation of neuromuscular junction, nuclear envelope, and spliceosome.

Schatzl T, Todorow V, Kaiser L, Weinschrott H, Schoser B, Deigner H Commun Biol. 2024; 7(1):640.

PMID: 38796645 PMC: 11127974. DOI: 10.1038/s42003-024-06325-z.

References

Geng L, Yao Z, Snider L, Fong A, Cech J, Young J . DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell. 2012; 22(1):38-51. PMC: 3264808. DOI: 10.1016/j.devcel.2011.11.013. View

Winokur S, Chen Y, Masny P, Martin J, Ehmsen J, Tapscott S . Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet. 2003; 12(22):2895-907. DOI: 10.1093/hmg/ddg327. View

Ribas R, Moncaut N, Siligan C, Taylor K, Cross J, Rigby P . Members of the TEAD family of transcription factors regulate the expression of Myf5 in ventral somitic compartments. Dev Biol. 2011; 355(2):372-80. PMC: 3123743. DOI: 10.1016/j.ydbio.2011.04.005. View

Dandapat A, Bosnakovski D, Hartweck L, Arpke R, Baltgalvis K, Vang D . Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene. Cell Rep. 2014; 8(5):1484-96. PMC: 4188423. DOI: 10.1016/j.celrep.2014.07.056. View

Knopp P, Krom Y, Banerji C, Panamarova M, Moyle L, den Hamer B . DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis. J Cell Sci. 2016; 129(20):3816-3831. PMC: 5087662. DOI: 10.1242/jcs.180372. View

Leidenroth A, Hewitt J . A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene. BMC Evol Biol. 2010; 10:364. PMC: 3004920. DOI: 10.1186/1471-2148-10-364. View

Zeng W, de Greef J, Chen Y, Chien R, Kong X, Gregson H . Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet. 2009; 5(7):e1000559. PMC: 2700282. DOI: 10.1371/journal.pgen.1000559. View

van Overveld P, Lemmers R, Sandkuijl L, Enthoven L, Winokur S, Bakels F . Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet. 2003; 35(4):315-7. DOI: 10.1038/ng1262. View

Barro M, Carnac G, Flavier S, Mercier J, Vassetzky Y, Laoudj-Chenivesse D . Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. J Cell Mol Med. 2008; 14(1-2):275-89. PMC: 2910739. DOI: 10.1111/j.1582-4934.2008.00368.x. View

10.

de Greef J, Lemmers R, van Engelen B, Sacconi S, Venance S, Frants R . Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat. 2009; 30(10):1449-59. DOI: 10.1002/humu.21091. View

11.

Banerji C, Panamarova M, Hebaishi H, White R, Relaix F, Severini S . PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle. Nat Commun. 2017; 8(1):2152. PMC: 5735185. DOI: 10.1038/s41467-017-01200-4. View

12.

Thijssen P, Balog J, Yao Z, Pham T, Tawil R, Tapscott S . DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy. Skelet Muscle. 2015; 4:19. PMC: 4364343. DOI: 10.1186/2044-5040-4-19. View

13.

Bosnakovski D, Xu Z, Gang E, Galindo C, Liu M, Simsek T . An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 2008; 27(20):2766-79. PMC: 2572182. DOI: 10.1038/emboj.2008.201. View

14.

Snider L, Geng L, Lemmers R, Kyba M, Ware C, Nelson A . Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 2010; 6(10):e1001181. PMC: 2965761. DOI: 10.1371/journal.pgen.1001181. View

15.

van Deutekom J, Wijmenga C, van Tienhoven E, Gruter A, Hewitt J, Padberg G . FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet. 1993; 2(12):2037-42. DOI: 10.1093/hmg/2.12.2037. View

16.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T . Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016; 48(5):569-74. DOI: 10.1038/ng.3535. View

17.

Jones T, Chen J, Rahimov F, Homma S, Arashiro P, Beermann M . Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum Mol Genet. 2012; 21(20):4419-30. PMC: 3459465. DOI: 10.1093/hmg/dds284. View

18.

Block G, Narayanan D, Amell A, Petek L, Davidson K, Bird T . Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Hum Mol Genet. 2013; 22(23):4661-72. PMC: 3820129. DOI: 10.1093/hmg/ddt314. View

19.

Zhu C, Mouly V, Cooper R, Mamchaoui K, Bigot A, Shay J . Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell. 2007; 6(4):515-23. DOI: 10.1111/j.1474-9726.2007.00306.x. View

20.

Zhang Y, Lee J, Toso E, Lee J, Choi S, Slattery M . DNA-binding sequence specificity of DUX4. Skelet Muscle. 2016; 6:8. PMC: 4730607. DOI: 10.1186/s13395-016-0080-z. View